-- Adherium Limited (ASX:ADR) a leader in digital health technologies, is excited to announce an agreement with NuvoAir Medical, a value-based specialty management platform focused on cardiopulmonary conditions headquartered in Boston, Massachusetts. This agreement has now commenced, which requires NuvoAir to purchase a minimum of 1,000 next generation Hailie® Smartinhaler® sensors, marking another stride in Adherium's rapid commercial expansion strategy in the US.
Adherium's CEO, Rick Legleiter, emphasised the importance of this new customer within the context of the Company's business by commenting, "This partnership signifies another step forward in Adherium's accelerated rollout of our commercial strategy with another significant partner in the United States in addition to Allergy Partners and SENTA, showcasing the growing recognition of the value our digital technology brings to respiratory healthcare."
The advanced features of the next generation Hailie Smartinhalers focus on physiological data capture, including inhalation flow rate and inhalation duration alongside medication adherence monitoring. This is an important step in assisting asthma and COPD sufferers with increased support with their medication usage and disease management. Hailie is the only US FDA 510(k) cleared, drug-agnostic digital Smartinhaler available today providing insights on patient inhaler technique.
